Default company panoramic image


RAFAGEN is established to commercialize its patented synthetic gene promoter technology in biologics drug development and manufacturing.

  • Stage Full Product Ready
  • Industry Biotechnology
  • Location Rockville, MD, USA
  • Currency USD
  • Founded October 2007
  • Employees 4
  • Website

Company Summary

RAFAGEN's core technology has applications in two different but critical areas of biopharmaceuticals. In drug development, the technology can be applied to minimize harmful drug effects. In biologics manufacturing procedure, it can minimize the cost by maximizing production efficiency. RAFAGEN strives first to establish a strong revenue stream in biologics manufacturing field, and then to peruse its long term goal of cancer drug development.


  • Default avatar
    Sung Ho Hahm

    Dr. Hahm has more than 25 years of experience in biomedical research and commercial development. He obtained Ph.D. degree in biomedical science at the University of South Carolina. He worked as a visiting/staff fellow at the National Institute of Mental Health and as a research faculty at Johns Hopkins University. Dr. Hahm has been involved in establishing two other start-up biotech companies as a founding member during the past ten years.

  • Default avatar
    Oltac Unsal
    Avcting Vice President

    Mr. Oltac Unsal’s financial career spans structured finance and principal investments at Credit Suisse First Boston, Goldman Sachs, and Smyrna Capital. As a successful co-founder and/or the first executive business employee of four Silicon Valley startups, he brings a deep entrepreneurial know-how to RAFAGEN. He holds an MBA from Stanford Business School and a BA in Philosophy, Economics and Politics from Whitman College.


  • Default avatar
    Joseph H. Kim, Ph.D. Attorney
    Default avatar
    Samuel Kim, Sky Investment

Previous Investors

  • Default avatar
    Samyang Optics Co. Ltd.
    Default avatar
    Angel Investors (13)